Issues related to the following bills: oS.1040: Drug Competition Enhancement Act oS.1041: Affordable Prescriptions for Patients Act oS.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act oS.1096: Preserve Access to Affordable Generics and Biosimilars Act oH.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act oH.R.3152/S.1546: Patent Eligibility Restoration (PERA) Act oH.R.3269: ETHIC Act
2025 · 4th Quarter (Oct 1 - Dec 31)
T1INTERNATIONAL USA
Filed by T1INTERNATIONAL USA.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 19, 2026
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- T1INTERNATIONAL USA
- Client
- T1INTERNATIONAL USA
- Filing UUID
- 7766ba25-ac2a-4887-8501-509f736b478a
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.